GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » Interest and Commission Paid

Hyloris Pharmaceuticals (XBRU:HYL) Interest and Commission Paid


View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Interest and Commission Paid?

Interest and Commission Paid only applicable to companies reporting Cash Flow from Operations in direct method.


Hyloris Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.